Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion type Assertion NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_head.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion description "[Embedded in this study was peripheral blood sampling for TMPRSS2-ERG and SPINK1, two genes that are believed to define prostate cancer genotypes, to assess their utility as biomarkers This study suggests that at the delivered doses, cytarabine has limited efficacy and significant myelotoxicity suggesting, it does not have a role in the treatment of docetaxel-refractory CRPC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_provenance.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion evidence source_evidence_literature NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_provenance.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion SIO_000772 22313860 NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_provenance.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion wasDerivedFrom befree-2016 NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_provenance.
- NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_assertion wasGeneratedBy ECO_0000203 NP959260.RA9YCP5tvp3kWXUjM01Kr8-vI34V4grDIkvBoXob-svHw130_provenance.